DAVIS STEPHEN
SEC CIK 1131146 · EDGAR
BoughtSold
Most active insiders at ACAD, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Schneyer Mark C. | EVP, CFO | — | $1.13M |
| 2 | Daly James M | Dir | — | $671.1K |
| 3 | Kihara James | PRINCIPAL ACCOUNTING Off | — | $602.8K |
| 4 | Thompson Elizabeth H.Z. | EVP, Head of Research, Dev | — | $506.4K |
| 5 | Owen Adams Catherine | CEO, Dir | — | $249.9K |
| 6 | Rhodes Jennifer J | EVP, CLO, SEC | — | $245.0K |
| 7 | Ndu Adora | Dir | — | — |
| 8 | GAROFALO ELIZABETH A. | Dir | — | — |
| 9 | Poole Jonathan | Dir | — | — |
| 10 | Brege Laura | Dir | — | — |
DAVIS STEPHEN made no open-market trades at ACAD in the last 12 months.
Transactions 37
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-08-20 | 2024-08-16 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | A - Grant | $0.00 | +62.1K | 173.5K | +56% | $0 |
| 2024-08-20 | 2024-08-19 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale | $15.28 | -31.7K | 186.6K | -15% | -$485.1K | |
| D | 2024-05-03 | 2024-05-02 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $16.94 | -11.4K | 155.2K | -7% | -$193.6K |
| D | 2024-05-03 | 2024-05-01 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +22.4K | 166.7K | +16% | — |
| DM | 2024-04-09 | 2024-04-05 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +52.0K | 170.8K | +44% | — |
| DM | 2024-04-09 | 2024-04-08 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $17.87 | -26.6K | 162.0K | -14% | -$474.9K |
| D | 2024-03-27 | 2024-03-27 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale | $17.90 | -17.7K | 118.8K | -13% | -$317.1K |
| D | 2024-03-27 | 2024-03-25 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | A - Grant | $0.00 | +34.7K | 136.6K | +34% | $0 |
| D | 2024-02-27 | 2024-02-23 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +10.9K | 107.5K | +11% | — |
| D | 2024-02-27 | 2024-02-26 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $24.67 | -5,577 | 101.9K | -5% | -$137.6K |
| D | 2024-01-09 | 2024-01-08 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $29.96 | -3,732 | 96.5K | -4% | -$111.8K |
| D | 2024-01-09 | 2024-01-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +9,528 | 100.3K | +11% | — |
| D | 2023-10-06 | 2023-10-05 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +104.0K | 140.7K | +283% | — |
| D | 2023-10-06 | 2023-10-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $21.96 | -51.6K | 89.1K | -37% | -$1.13M |
| D | 2023-07-18 | 2023-07-14 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $30.04 | -100.0K | 36.7K | -73% | -$3.00M |
| D | 2023-07-18 | 2023-07-14 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | $20.77 | +100.0K | 136.7K | +273% | +$2.08M |
| M | 2023-07-13 | 2023-07-11+ | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale | $25.04 | -71.6K | 36.7K | -66% | -$1.79M |
| D | 2023-05-02 | 2023-04-29 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | +15.6K | 116.1K | +16% | $0 |
| D | 2023-05-02 | 2023-05-01 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $21.18 | -7,806 | 108.3K | -7% | -$165.3K |
| D | 2023-04-07 | 2023-04-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $18.16 | -8,582 | 100.5K | -8% | -$155.8K |
| D | 2023-04-07 | 2023-04-05 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +17.3K | 109.1K | +19% | — |
| D | 2023-02-27 | 2023-02-24 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $18.78 | -3,851 | 91.7K | -4% | -$72.3K |
| D | 2023-02-27 | 2023-02-23 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +10.9K | 95.6K | +13% | — |
| D | 2023-01-10 | 2023-01-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +9,528 | 88.5K | +12% | — |
| D | 2023-01-10 | 2023-01-09 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $17.13 | -3,904 | 84.6K | -4% | -$66.9K |
| D | 2022-12-20 | 2022-12-16 | HRTX | HERON THERAPEUTICS, INC. /DE/ | DAVIS STEPHEN | Dir | A - Grant | $0.00 | +38.6K | 52.0K | +287% | $0 |
| D | 2022-10-18 | 2022-10-15 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $15.81 | -2,804 | 79.0K | -3% | -$44.3K |
| D | 2022-10-18 | 2022-10-15 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +5,938 | 81.8K | +8% | — |
| D | 2022-05-03 | 2022-05-02 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $18.18 | -5,483 | 75.9K | -7% | -$99.7K |
| D | 2022-05-03 | 2022-04-29 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +15.6K | 81.4K | +24% | — |
| D | 2022-02-25 | 2022-02-23 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | $0.00 | +10.9K | 69.7K | +19% | $0 |
| D | 2022-02-25 | 2022-02-23 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $23.80 | -3,928 | 65.7K | -6% | -$93.5K |
| D | 2022-01-10 | 2022-01-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +9,527 | 62.4K | +18% | — |
| D | 2022-01-10 | 2022-01-06 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $23.05 | -3,718 | 58.7K | -6% | -$85.7K |
| D | 2021-12-23 | 2021-12-22 | HRTX | HERON THERAPEUTICS, INC. /DE/ | DAVIS STEPHEN | Dir | A - Grant | $0.00 | +10.5K | 13.5K | +348% | $0 |
| D | 2021-10-19 | 2021-10-15 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | M - OptEx | — | +5,938 | 55.9K | +12% | — |
| D | 2021-10-19 | 2021-10-18 | ACAD | ACADIA PHARMACEUTICALS INC | DAVIS STEPHEN | CEO, Dir | S - Sale+OE | $17.41 | -2,963 | 52.9K | -5% | -$51.6K |
Purchase Sale Sale after option exercise All abbreviations